Eduardo Mysler

19.1k citations

106 papers · 5.8k indexed · 5 hit papers · h-index 32

Impact in

Rheumatology top 0.1%
- Systemic Lupus Erythematosus Research
- Rheumatoid Arthritis Research and Therapies
Nephrology top 0.5%
- Renal Diseases and Glomerulopathies

Papers in

Rheumatology 90
- Rheumatoid Arthritis Research and Therapies 70
- Systemic Lupus Erythematosus Research 35
Hematology 40
- Autoimmune and Inflammatory Disorders Research 40

Co-authors: Mark C. Genovese Gerd R Burmester David Jayne Gerhard Krammer Е. Л. Насонов Thasia Woodworth Emma Alecock James D. McKay
Journals: Annals of the Rheumatic Diseases (32 papers)RMD Open (8 papers)Lara D. Veeken (7 papers)Current Rheumatology Reports (4 papers)Rheumatology and Therapy (4 papers)
Partner nations: United States United Kingdom Germany

In The Last Decade

Eduardo Mysler

103 papers receiving 5.6k citations

Hit Papers

5 papers align trajectories log scale

Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis 2023 · 124 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2023 RMD Open
2022 Annals of the Rheumatic Diseases
2019 Arthritis & Rheumatology
2009 Journal of the American Society of Nephrology
2008 Arthritis & Rheumatism

Peers

Countries citing papers authored by Eduardo Mysler

Since Specialization

Citations

This map shows the geographic impact of Eduardo Mysler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eduardo Mysler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eduardo Mysler more than expected).

Fields of papers citing papers by Eduardo Mysler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eduardo Mysler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eduardo Mysler. The network helps show where Eduardo Mysler may publish in the future.

Co-authors

The 25 scholars most cited alongside Eduardo Mysler, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Eduardo Mysler Line = papers co-authored together Eduardo Mysler links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Sex differences in the efficacy, safety and persistence of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of phase III and long-term extension trials BMJ Open ·V. Strand, Hendrik Schulze-Koops, Samar Al‐Emadi, C. Kinch, David Gruben, Rebecca Germino, C. A. Connell, Eduardo Mysler	2025	1
2	Immunogenicity of adjuvanted recombinant zoster vaccine in patients with rheumatoid arthritis treated with upadacitinib: 60-week results from a randomised controlled trial substudy RMD Open ·Kevin Winthrop, Justin Klaff, S. Penn, Yanxi Liu, Conrado García-García, Eduardo Mysler, Alvin F. Wells, Xianwei Bu, Irina Fish, Michael Chen, Anthony L. Cunningham	2025	1
3	Risk of Venous Thromboembolism With Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Cardiovascular Risk‐Enriched Rheumatoid Arthritis Patients Arthritis & Rheumatology ·Christina Charles‐Schoeman, Roy Fleischmann, Eduardo Mysler, Maria Greenwald, Steven R. Ytterberg, Gary G. Koch, Deepak L. Bhatt, Cunshan Wang, Ted R. Mikuls, All‐shine Chen, Carol A. Connell, John Woolcott, Sujatha Menon, Yan Chen, Kristen Lee, Zoltán Szekanecz	2024	13
4	Targeting the Type I Interferon Pathway in Glomerular Kidney Disease: Rationale and Therapeutic Opportunities Kidney International Reports ·James A. Tumlin, Brad H. Rovin, Hans‐Joachim Anders, Eduardo Mysler, David Jayne, Tsutomu Takeuchi, Catharina Lindholm, Gudrun Weiss, Alessandro Sorrentino, Kevin Woollard, Nicola Ferrari	2024	2
5	Clinical scenarios-based guide for tofacitinib in rheumatoid arthritis Therapeutic Advances in Chronic Disease ·Mahta Mortezavi, Eduardo Mysler	2023	4
6	Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial Lupus Science & Medicine ·David Jayne, Brad H. Rovin, Eduardo Mysler, Richard Furie, Frédéric Houssiau, Teodora Trasieva, J. Knagenhjelm, Erik Schwetje, Weifeng Tang, Raj Tummala, Catharina Lindholm	2023	23
7	Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis RMD Open ·Gerd R Burmester, Stanley Cohen, Kevin Winthrop, Peter Nash, Alan D. Irvine, Atul Deodhar, Eduardo Mysler, Yoshiya Tanaka, John Liu, Ana P. Lacerda, Hannah Palac, Tim Shaw, Philip J. Mease, Emma Guttman‐Yassky Hit paper breakdown →	2023	124
8	MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis RMD Open ·Christina Charles‐Schoeman, Ernest Choy, Iain B. McInnes, Eduardo Mysler, Peter Nash, Kunihiro Yamaoka, Ralph Lippe, Nasser Khan, Anna Shmagel, Hannah Palac, J. Suboticki, Jeffrey R. Curtis	2023	17
9	Upadacitinib in Rheumatoid Arthritis: A Benefit–Risk Assessment Across a Phase III Program Drug Safety ·Philip G. Conaghan, Eduardo Mysler, Yoshiya Tanaka, Barbara Da Silva‐Tillmann, Tim Shaw, John Liu, Ryan Ferguson, Jeffrey Enejosa, Stanley Cohen, Peter Nash, William F. C. Rigby, Gerd R Burmester	2021	33
10	Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience? Drugs ·Eduardo Mysler, Valderílio Feijó Azevedo, Silvio Danese, Daniel Alvarez, Noriko Iikuni, Beverly Ingram, Markus Mueller, Laurent Peyrin‐Biroulet	2021	28
11	Safety of Tofacitinib in the Treatment of Rheumatoid Arthritis in Latin America Compared With the Rest of the World Population JCR Journal of Clinical Rheumatology ·Oswaldo Castañeda, F.J. Rodríguez Romero, Ariel Salinas, Gustavo Citera, Eduardo Mysler, Oscar Rillo, S. Radominski, Mario H. Cardiel, Juan José Jaller, Carlos Álvarez, Darío Ponce de León, Graciela Castelli, Erika G. García, Kenneth Kwok, Ricardo Rojo	2017	13
12	A randomised phase IIb study of mavrilimumab, a novel GM–CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis Annals of the Rheumatic Diseases ·Gerd R Burmester, Iain B. McInnes, Joel M. Kremer, Pedro C. Miranda, Mariusz Korkosz, Jiří Vencovský, Andrea Rubbert‐Roth, Eduardo Mysler, Matthew A. Sleeman, A. Godwood, Dominic Sinibaldi, Xiang Guo, Wendy I. White, Bing Wang, Chi‐Yuan Wu, Patricia C. Ryan, D. Close, Michael E. Weinblatt	2017	105
13	Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician Current Rheumatology Reports ·Robert J. Moots, Valderílio Feijó Azevedo, Javier Coindreau, Thomas Dörner, Ehab Mahgoub, Eduardo Mysler, Morton Scheinberg, Lisa Marshall	2017	67
14	Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology Rheumatology International ·Eduardo Mysler, Carlos Pineda, Takahiko Horiuchi, Ena Singh, Ehab Mahgoub, Javier Coindreau, Ira Jacobs	2016	60
15	Biopharmaceuticals for rheumatic diseases in Latin America, Europe, Russia, and India: Innovators, biosimilars, and intended copies Joint Bone Spine ·Gilberto Castañeda‐Hernández, Zoltán Szekanecz, Eduardo Mysler, Valderílio Feijó Azevedo, Renato Guzmán, Miguel A. Gutierrez, Wilfredo Rodríguez, Д. Е. Каратеев	2014	41
16	The effect of antidrug antibodies on the sustainable efficacy of biologic therapies in rheumatoid arthritis: practical consequences Expert Review of Clinical Immunology ·Mauro Waldemar Keiserman, Cătălin Codreanu, Rohini Handa, D. X. Xibille Friedmann, Eduardo Mysler, F.J. Briceño, Servet Akar	2014	34
17	Subcutaneous Abatacept for the Treatment of Rheumatoid Arthritis: Longterm Data from the ACQUIRE Trial The Journal of Rheumatology ·Mark C. Genovese, César Pacheco‐Tena, A. Covarrubias, Gustavo León, Eduardo Mysler, Mauro Keiserman, Robert Valente, Peter Nash, Jesus Abraham Simón Campos, Jane Herron Box, Clarence William Legerton, Evgeny Nasonov, Patrick Durez, Ingrid Delaet, Julie Teng, Rieke Alten	2014	23
18	Sifalimumab, a Human Anti–Interferon‐α Monoclonal Antibody, in Systemic Lupus Erythematosus: A Phase I Randomized, Controlled, Dose‐Escalation Study Arthritis & Rheumatism ·Michelle Petri, Daniel J. Wallace, Alberto Spindler, Vishala Chindalore, Kenneth Kalunian, Eduardo Mysler, C. Michael Neuwelt, Gabriel J. Robbie, Wendy I. White, Brandon W. Higgs, Yihong Yao, Liangwei Wang, D Ethgen, Warren Greth	2013	200
19	A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study) Annals of the Rheumatic Diseases ·Gerd R Burmester, Andrea Rubbert‐Roth, Alain Cantagrel, Stephen Hall, Piotr Leszczyński, Daniel Feldman, Madura J Rangaraj, Georgia Roane, Charles Ludivico, Peng Lü, Lucy Rowell, Min Bao, Eduardo Mysler	2013	198
20	Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial The Lancet ·Thomas J. Schnitzer, Gerd R Burmester, Eduardo Mysler, Marc C. Hochberg, Michael Doherty, Elena Ehrsam, Xavier Gitton, Gerhard Krammer, B. Mellein, Patrice Matchaba, Alberto Gimona, Christopher J. Hawkey	2004	493

About Eduardo Mysler

Eduardo Mysler is a scholar working on Rheumatology, Hematology, Genetics, Immunology and Nephrology, having authored 106 papers that have together received 5.8k indexed citations. Recurring topics across this work include Rheumatoid Arthritis Research and Therapies (70 papers), Autoimmune and Inflammatory Disorders Research (40 papers), Systemic Lupus Erythematosus Research (35 papers), Biosimilars and Bioanalytical Methods (20 papers), Lymphoma Diagnosis and Treatment (20 papers), Chronic Lymphocytic Leukemia Research (17 papers), Monoclonal and Polyclonal Antibodies Research (11 papers) and Health Systems, Economic Evaluations, Quality of Life (10 papers). The work is most often cited by research in Rheumatology (3.5k citations), Nephrology (722 citations), Immunology (2.0k citations), Hematology (1.0k citations) and Genetics (552 citations). Eduardo Mysler has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include Mark C. Genovese, Gerd R Burmester, David Jayne, Gerhard Krammer, Е. Л. Насонов, Thasia Woodworth, Emma Alecock, James D. McKay, Nilzio A Da Silva and Juan J. Gómez‐Reino. Their work appears in journals such as Annals of the Rheumatic Diseases, RMD Open, Lara D. Veeken, Current Rheumatology Reports and Rheumatology and Therapy.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact